Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

Combination Cytotoxic and Antiangiogenic Therapy in the Management of Epithelial Ovarian Cancer

“…Of considerable interest, this study was unique in the spectrum of all oncology trials exploring a role for antiangiogenic drugs in that it specifically addressed two different but highly clinically relevant issues associated with the use of bevacizumab. As outlined in Table 2 [10,11], patients treated with bevacizumab both during chemotherapy and after completion of cytotoxic therapy ("maintenance") experienced a statistically significant improvement in PFS compared with chemotherapy alone (no bevacizumab).…”

“…The second primary ovarian cancer phase 3 bevacizumab trial, which was conducted in Europe and Canada, differed in several important aspects compared with the GOG study ( Table 2) [11]. First, this study did not employ placebo control.…”

“…At the time of writing this review, the preliminary results of three phase 3 randomized trials, which examined a potential role for bevacizumab when combined with standard cytotoxic chemotherapy in the management of ovarian cancer, have been reported [10][11][12].…”

“…Two of these studies evaluated the addition of the antiangiogenic agent with carboplatin plus paclitaxel in the primary care setting (Table 2) [ 10,11], while the third trial explored the drug in recurrent disease when given with carboplatin plus gemcitabine (Table 3) [12].…”

Specific features of current intraperitoneal therapy in patients with ovarian cancer

“…В исследовании ICON7 продемонстрировано преимущество применения бевацизумаба 7,5 мг / кг для больных с мелкими остаточными опухолями, ас-цитом и высоким риском прогрессирования [21,22]. Отличительные черты протокола GOG 0252 по срав-нению с GOG 0172 -это снижение дозы цисплатина со 100 до 75 мг и сокращение времени инфузии пакли-таксела с 24 до 3 ч. Предварительные результаты лече-ния 1560 пациенток с РЯ, из которых 72 % имели мор-фологический тип серозной цистаденокарциномы высокой степени злокачественности, а 57 % были прооперированы в оптимальном объеме, без видимых очагов опухоли, показали отсутствие разницы между в / б и в / в терапией на этапе оценки БРВ.…”